SpyGlass Pharma, Inc. (SGP)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

24.92 on 9 Oct 2026

16 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$39.87M

Free cash flow

$33.49M

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
9 Feb 2026	RA CAPITAL MANAGEMENT, L.P. Director	Bought	$59.04M	162%
9 Feb 2026	SANDELL SCOTT D 10% owner	Bought	$15.00M	18.4%
9 Feb 2026	Behbahani Ali Director	Bought	$15.00M	18.4%
9 Feb 2026	Chang Carmen 10% owner	Bought	$15.00M	18.4%
9 Feb 2026	Mathers Edward T 10% owner	Bought	$15.00M	18.4%
9 Feb 2026	Walker Paul Edward 10% owner	Bought	$15.00M	18.4%

33out of 100

Profitability 0

Financial strength 20

Growth n/a

Insiders 100

Strongest on insiders (100), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$221.48M

16 buys, 15 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan